Anurag Agrawal

Dr. Anurag Agrawal

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in International Journal of Pharmacy and Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
NJNem Kumar Jain
Nem Kumar Jain
AAAnurag Agrawal
Anurag Agrawal
GKGiriraj T Kulkarni
Giriraj T Kulkarni
MTMukul Tailang
Mukul Tailang
Objective: The aim of the present study was to assess bioactive compounds found in Tulsi as potential COVID-19 Mpr °inhibitor using molecular docking and to provide scientific justification in term of its active ingredient to target protein for prevention and symptomatic treatment of COVID-19. Methods: COVID-19 Mpr °was docked with eight phytochemicals of Ocimum sanctum Linn. Using Autodock 4.2. Determination of active site and visualization of molecular interactions between ligands and target enzyme was done by Biovia Discovery Studio 4.5. Results: Our result demonstrates that Vicenin, Caryophyllene, Cirsimaritin, Isothymusin and Isothymonin have a better binding affinity to target enzyme. However, only Vicenin exhibited better binding energy i.e.-7.02 kcal/mol to COVID-19 Main protease among other phytochemicals through some responsible interactions to inhibit the replication of SARS-CoV-2 in the human body, whereas Caryophyllene and Cirsimaritin exhibited similar binding affinity i.e.-6.46 kcal/mol but different interactions with target enzyme. Conclusion: Tulsi (Ocimum sanctum Linn.) is a preeminent traditional drug of Ayurveda for prophylaxis and treatment of various ailments, including respiratory disorders like cough, cold and flu. With no specific therapies available, reevaluating and repurposing traditional drugs could be an effective approach for the prevention and treatment of SARS-CoV-2 infection. Therefore our study provides scientific evidence for the potential use of Tulsi as an adjunct therapy for the prevention and symptomatic treatment of COVID-19. However, further in vitro and in vivo studies should be conducted to validate use of proposed compounds in drug discovery and as therapeutics against COVID-19.

24 May 2023 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
AAAnurag Agrawal
Anurag Agrawal
GKGiriraj T Kulkarni
Giriraj T Kulkarni
LALakshmayya
Lakshmayya

8 August 2024 in Diseases
Verified
Journal Article
Open access
PDF file
VSVara Prasad Saka
Vara Prasad Saka
NGNarasimha Kumar G.V
Narasimha Kumar G.V
Bharat Kumar Reddy SanapalliBharat Kumar Reddy Sanapalli
Bharat Kumar Reddy Sanapalli
AGAbanti Goswami
Abanti Goswami
ARAnirban Roy
Anirban Roy
SKSubhash Kaushik
Subhash Kaushik
This study investigated how Rhus toxicodendron (RT) (6C, 30C, and 200C) can boost the immune system of BALB/c mice that were given cyclophosphamide (CPM), which is an anticancer drug that weakens the immune system. RT, known for its historical use in traditional homeopathic remedies, has demonstrated immunomodulatory and anti-inflammatory effects in various experimental models. To test the immune-boosting effects of RT, CPM (80 mg/kg) was given intraperitoneally to mice on days 4, 8, and 12 of the study but not to the normal control group. CPM-induced immunosuppression led to significant decreases in red blood cell (RBC), white blood cell (WBC), and hemoglobin (Hb) levels, and reduced spleen and thymus indices. Phagocytic activity, cytokine concentrations, and spleen architecture were also adversely affected. RT treatment, particularly at 200C, significantly ameliorated these effects, improving RBC, WBC, and Hb levels. Furthermore, RT partially prevented CPM-induced atrophy of immune organs. Treatment positively influenced cytokine production at both the protein and mRNA levels, restoring immune balance. Histopathological results confirmed that RT stimulated the immune system. The cells were more stable, and the white pulp in the spleen was arranged in a regular pattern. These findings suggest that RT may serve as an adjunctive immunostimulant therapy for conditions characterized by immunosuppression. However, further investigations in other immunocompromised states must validate these results before considering human clinical trials.

23 April 2020 in ChemRxiv
Verified
Preprint
Open access
PDF file
AAAnurag Agrawal
Anurag Agrawal
NJNem Kumar Jain
Nem Kumar Jain
NKNeeraj Kumar
Neeraj Kumar
GKGiriraj T Kulkarni
Giriraj T Kulkarni
This study belongs to identification of suitable COVID-19 inhibitorsCoronavirus became pandemic very soon and is a potential threat to human lives across the globe. No approved drug is currently available therefore an urgent need has been developed for any antiviral therapy for COVID-19. For the molecular docking study, ten herbal molecules have been included in the current study. The three-dimensional chemical structures of molecules were prepared through ChemSketch 2015 freeware. Molecular docking study was performed using AutoDock 4.2 simulator and Discovery studio 4.5 was employed to predict the active site of target enzyme. Result indicated that all-natural molecules found in the active site of enzyme after molecular docking. Oxyacanthine and Hypericin (-10.990 and -9.05 and kcal/mol respectively) have shown good binding efficacy among others but Oxyacanthine was the only natural product which made some of necessary interactions with residues in the enzyme require for target inhibition. Therefore Oxyacanthine may be considered to be potential inhibitor of main protease enzyme of virus but need to be explored for further drug development process.

1 February 2025 in Current Organocatalysis
Verified
Journal Article
Closed access
PDF file
ABAnkita Bhandari
Ankita Bhandari
NKNitin Kumar
Nitin Kumar
AAAnurag Agrawal
Anurag Agrawal
PBPayal Bhatnagar
Payal Bhatnagar
SSShikha International college of Sharma
Shikha International college of Sharma
Background: Heterocyclic compounds with O, N, and/or S atoms are highly valuable in drug discovery and development. Their pyrazole moieties find applications in various fields, such as herbicides, corrosion inhibitors, electron transport materials, polymers, and luminescent materials. Consequently, there is a pressing need in medicinal chemistry to develop new antibacterial agents to enhance therapeutic efficacy and safety. Methods: A newer biologically active 1-(4-substitutedphenyl)-5-chloro-3-methyl-1Hpyrazole-4-carboxylic acid analogue was synthesized by the para-substituted phenylhydrazine. All the synthesized compounds were characterized by NMR, mass spectral, and IR spectrum examinations, as well as C, H, and N analyses. The synthesized compounds were screened for antibacterial and antifungal activities. Furthermore, a molecular docking study was performed to elucidate the binding modes of synthesized ligands in the active pockets of DNA gyrase and CYP51 (PDB IDs: 4uro and 5tz1, respectively) for exhibiting the binding modes and predicting the mechanism of action of synthesized ligands. Results: Five compounds (2Rb, 2Re, 2Rg, 2Rh, and 2Ri) demonstrated significant antibacterial action against gram-positive B. subtilis and gram-negative E. coli and antifungal activity against C. albicans and A. niger compared to the standard drugs cefixime and ketoconazole. Furthermore, molecular docking was employed to reveal how the newly synthesized ligands bind within the active pockets. It was found that compound 2Rb demonstrated significant antibacterial activity, and compound 2Rg had good antifungal activity. Conclusion: The current study highlights the unique structural characteristics and significant biological activity of the synthesized compounds. In the pursuit of novel antibacterial and antifungal molecules, these compounds could prove beneficial to society.

15 May 2026 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
GSGaurav Kant Sarogi
Gaurav Kant Sarogi
AAAnurag Agrawal
Anurag Agrawal
MKMamta Kumari
Mamta Kumari
SSShikha International college of Sharma
Shikha International college of Sharma
Aakash SharmaAakash Sharma
Aakash Sharma
BBBimal Banik
Bimal Banik
The mammalian gut is a highly dynamic physiological ecosystem that harbors an enormous number of commensal bacteria that play an essential role in the development of various cells of the immune system. The gut bacteria, both resident and diet-derived, share a habitat with immune cells located within the lamina propria layer of the intestinal villi. The intestinal epithelial cells do not come into direct contact with the gut microbiota, but microbial metabolites play a significant role in their maturation and appropriate function. According to the World Health Organization, probiotics are "live microorganisms which, when administered in adequate amounts, confer a health benefit on the host." The microbiota found within the human gut has been evolutionarily selected based on their suitability to survive within the GT. Lactic acid bacteria, belonging to Pediococcus, Lactobacilli, Streptococci, Bifidobacteria, Enterococcus, and yeast cells like Saccharomyces boulardii, are found to be predominantly used as a source of probiotics. However, these properties are strain-specific and not a general feature of all bacteria. To maintain immunological homeostasis and control both the innate and adaptive immune responses, immune cells, nutrients, and commensal microbes continuously interact in dynamic processes in a stable environment. This interaction allows the host to enhance immunity through improved immunological responses to diseases, including inflammatory and infectious conditions. Among specific benefits are infection prevention, alleviation of symptoms associated with Helicobacter pylori suppression, irritable bowel syndrome management, cancer prevention, reduction of gut inflammation, and allergy, diabetes, and drug-resistant pathogen prevention. This review focuses on compiling key findings up to date and discussing their implications in the interaction between probiotics and immune cells towards immune function.